Author

Harshada Joshi

Institution: PAREXEL International (India)

Observed institution: PAREXEL International (India)

OpenAlex ID: A5079382575

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial

2023 · Jason A Chesney, Igor Puzanov, et al. · Journal for ImmunoTherapy of Cancer · 98

Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti–PD-1 therapy: MASTERKEY-115,

2024 · Caroline Robert, Brian Gastman, et al. · European Journal of Cancer · 44

Primary analysis of a phase 2, open-label, multicenter trial of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) for the treatment (Tx) of patients (pts) with advanced melanoma (MEL) who progressed on prior anti–PD-1 therapy: MASTERKEY-115.

2022 · Brian Gastman, Caroline Robert, et al. · Journal of Clinical Oncology · 15

Works count: 3

Citation count: 157

H-index: 3

I10-index: 3